



CORRECTION



Correction: Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment

Dotan Moskovich, Yael Finkelshtein, Adi Alfandari, Amit Rosemarin, Tzuri Lifschytz, Avivit Weisz, Santanu Mondal, Harinarayana Ungati, Aviva Katzav, Debora Kidron, Govindasamy Mugesh, Martin Ellis, Bernard Lerer  and Osnat Ashur-Fabian 

© The Author(s), under exclusive licence to Springer Nature Limited 2023

Oncogene (2023) 42:1508; <https://doi.org/10.1038/s41388-023-02629-2>

Correction to: *Oncogene* <https://doi.org/10.1038/s41388-021-02020-z>, published online 23 September 2021

In the original manuscript, there was an error in the name of one of the cell lines. Instead of OVCAR3 it should have been ES-2. This was amended in the published article and the supplementary material.